Riepe Matthias, Hoerr Robert, Schlaefke Sandra
Division of Geriatric Psychiatry, Ulm University, Ulm, Germany.
Medical Consultant, Bretten, Germany.
World J Biol Psychiatry. 2025 Mar;26(3):119-129. doi: 10.1080/15622975.2024.2446830. Epub 2025 Feb 3.
Mild dementia is distressing for patients and their relatives. Due to its chronic and progressive nature, healthcare systems are at risk of being overwhelmed by the increasing number of affected patients. Thus, there is a need for safe and well-tolerated treatments that can be initiated at the earliest stages.
This meta-analysis of clinical trials aimed to assess the treatment effects of extract EGb 761 in patients with mild dementia.
Eligible randomised placebo-controlled trials were included in this meta-analysis. Data of patients with mild dementia (defined as the SKT Short Cognitive Performance Test total scores from 9 to 15) were selected.
The meta-analysis was performed with pooled data from four eligible trials comprising 782 patients with mild dementia. Treatment with 240 mg EGb 761 daily was significantly superior to placebo in cognition ( = 0.04), global assessment ( = 0.01), activities of daily living ( = 0.01) and quality of life ( = 0.02). Standardised effects were medium to large. The frequency of adverse events was alike in patients treated with EGb 761 and placebo ( = 0.66).
The meta-analysis demonstrates that patients with mild dementia benefit from EGb 761 in terms of cognition, activities of daily living, global assessment and quality of life.
轻度痴呆对患者及其亲属来说令人苦恼。由于其慢性和渐进性的特点，医疗系统面临着受影响患者数量不断增加而不堪重负的风险。因此，需要有能在疾病最早阶段开始使用的安全且耐受性良好的治疗方法。
这项临床试验的荟萃分析旨在评估银杏叶提取物EGb 761对轻度痴呆患者的治疗效果。
本荟萃分析纳入了符合条件的随机安慰剂对照试验。选取了轻度痴呆患者（定义为SKT简易认知功能测试总分在9至15分之间）的数据。
荟萃分析采用了来自四项符合条件的试验的汇总数据，这些试验共纳入782例轻度痴呆患者。每日服用240毫克EGb 761在认知（P = 0.04）、整体评估（P = 0.01）、日常生活活动能力（P = 0.01）和生活质量（P = 0.02）方面均显著优于安慰剂。标准化效应为中等至较大。服用EGb 761和安慰剂的患者不良事件发生率相似（P = 0.66）。
荟萃分析表明，轻度痴呆患者在认知、日常生活活动能力、整体评估和生活质量方面可从EGb 761中获益。
